GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biodesix Inc (NAS:BDSX) » Definitions » Current Ratio

Biodesix (Biodesix) Current Ratio : 1.19 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Biodesix Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Biodesix's current ratio for the quarter that ended in Dec. 2023 was 1.19.

Biodesix has a current ratio of 1.19. It generally indicates good short-term financial strength.

The historical rank and industry rank for Biodesix's Current Ratio or its related term are showing as below:

BDSX' s Current Ratio Range Over the Past 10 Years
Min: 0.56   Med: 1.87   Max: 2.68
Current: 1.19

During the past 6 years, Biodesix's highest Current Ratio was 2.68. The lowest was 0.56. And the median was 1.87.

BDSX's Current Ratio is ranked worse than
77.31% of 238 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.245 vs BDSX: 1.19

Biodesix Current Ratio Historical Data

The historical data trend for Biodesix's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biodesix Current Ratio Chart

Biodesix Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial 0.56 2.68 1.51 2.34 1.19

Biodesix Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.34 1.57 0.90 0.88 1.19

Competitive Comparison of Biodesix's Current Ratio

For the Diagnostics & Research subindustry, Biodesix's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biodesix's Current Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biodesix's Current Ratio distribution charts can be found below:

* The bar in red indicates where Biodesix's Current Ratio falls into.



Biodesix Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Biodesix's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=39.683/33.416
=1.19

Biodesix's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=39.683/33.416
=1.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biodesix  (NAS:BDSX) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Biodesix Current Ratio Related Terms

Thank you for viewing the detailed overview of Biodesix's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biodesix (Biodesix) Business Description

Traded in Other Exchanges
N/A
Address
2970 Wilderness Place, Suite 100, Boulder, CO, USA, 80301
Biodesix Inc is a data-driven diagnostic solutions company. Its artificial intelligence-based platform helps to discover, develop, and commercialize solutions for clinical unmet needs, with a focus on lung disease. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
Executives
Scott Hutton director, officer: President & CEO 9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Kieran O'kane officer: Chief Commercial Officer 2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Gary Anthony Pestano officer: Chief Development Officer 2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Robin Harper Cowie officer: CFO, Sec'y & Treasurer 2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Chris Vazquez officer: Chief Accounting Officer 2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Jack W Schuler director, 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Jon Faiz Kayyem director 5964 LA PLACE COURT, CARLSBAD CA 92008
Kennedy Lawrence T. Jr director, 10 percent owner C/O WESTWOOD MANAGEMENT, 1700 MADISON ROAD, SUITE 200, CINCINNATI OH 45206
Ryan H Siurek officer: Chief Accounting Officer 6200 SPRINT PARKWAY, OVERLAND PARK KS 66251
John Patience director, 10 percent owner, other: Chairman 28161 N. KEITH DRIVE, LAKE FOREST IL 60045
Matthew Strobeck director C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Charles M Watts director 3950 SOUTH COUNTRY CLUB, SUITE 470, TUCSON AZ 85714
Hany Massarany director 1910 INNOVATION PARK DR, TUCSON AZ 85737
Georgantas Robert William Iii director, officer: SVP, Rsrch & Trans'l Science 2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Jean M. Franchi director C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139